Medtronic

ESC Guidelines recommend renal denervation

for uncontrolled and resistant hypertension patients[1]

The future of hypertension care is now.

The European Society of Cardiology now includes renal denervation (RDN) as a class IIb recommendation that provides a safe and effective complementary option to control blood pressure.[1]

Patient Selection criteria

Uncontrolled hypertension

- With increased CV risk
- Treated with <3 antihypertensive drugs

Resistant hypertension

- Treated with ≥3 antihypertensive drugs including diuretic

And who have:

- eGFR ≥40 ml/min/1.73m^2
- Express a preference for RDN in a shared-decision making process

Additional recommendations

- Selection of patients should be done after assessment by a multidisciplinary team.
- Procedure should be performed in experienced medium to high volume centers.

Read the ESC guidelines

Elevate hypertension care options as you know them.

The Symplicity™ blood pressure procedure delivers **significant, safe, and sustained blood pressure reductions.**[2-6]

Explore the evidence

>9 mmHg

reduction in OSBP in patients off and on medications[2,3]

References:
1. McEvoy JW. et al, European Heart Journal, ehae178, https://doi.org/10.1093/eurheartj/ehae178
2. Böhm M, et al. Lancet. 2020;395:1444-1451.
3. Kandzari DE, et al. J Am Coll Cardiol. 2023;82:1809-1823.
4. Mahfoud F, et al. Lancet. 2022;399:1401-1410.
5. Mahfoud F, et al. EuroPCR 2023.
6. Mahfoud F, et al. Hypertension. 2023;80:1759-1770.

Medtronic

Europe
Medtronic International Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
www.medtronic.eu
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00

United Kingdom/Ireland
Medtronic Limited
Building 9
Croxley Park
Hatters Lane
Watford
Herts WD18 8WW
www.medtronic.co.uk
Tel: +44 (0)1923 212213
Fax: +44 (0)1923 241004